Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Legal / IP

Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar

Fineline Cube Aug 8, 2023

US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement...

Company Drug

VistaGen’s Fasedienol Phase III Success Sends Shares Soaring Over 600%

Fineline Cube Aug 8, 2023

Shares of San Francisco-based biotech VistaGen (NASDAQ: VTGN) experienced a dramatic increase of over 600%...

Company Legal / IP

Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute

Fineline Cube Aug 8, 2023

A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly &...

Company Drug

BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448

Fineline Cube Aug 8, 2023

China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...

Company

Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth

Fineline Cube Aug 8, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the...

Company Deals

Beijing’s Gene Cradle Secures Pre-Series B+ Funding Led by Cash Capital

Fineline Cube Aug 8, 2023

Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi...

Company Deals

Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors

Fineline Cube Aug 8, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a...

Policy / Regulatory

National Health Commission Unveils 10 Measures to Enhance Primary Healthcare Services

Fineline Cube Aug 8, 2023

The National Health Commission has issued a Notice outlining “Measures for Grassroots Health and Convenient...

Company Drug

Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae

Fineline Cube Aug 7, 2023

Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that...

Company Deals

ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China

Fineline Cube Aug 7, 2023

US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation...

Company Deals

Oramed Pharmaceuticals and Hefei Tianhui Biotech to Form Joint Venture for Oral Insulin Product

Fineline Cube Aug 7, 2023

Israel-based drug developer Oramed Pharmaceuticals Inc., (NASDAQ: ORMP) has revealed that a deal has been...

Company Drug

Astellas Pharma’s Izervay Receives FDA Approval for Geographic Atrophy Treatment

Fineline Cube Aug 7, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has announced that it has received new market approval...

Company

Regeneron Pharmaceuticals Halts Enrollment in REGN5678 Clinical Trial After Patient Deaths

Fineline Cube Aug 7, 2023

US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has reported in its Q2 2023 financial results the...

Company Drug

Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study

Fineline Cube Aug 7, 2023

China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US...

Company Medical Device

Jenscare Scientific and Lifetech Scientific Achieve Milestone with First Compassionate Use of LuX-Valve Plus

Fineline Cube Aug 7, 2023

Partners Jenscare Scientific Co., Ltd. (HKG: 9877), a leading structural heart disease device manufacturer based...

Policy / Regulatory

GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023

Fineline Cube Aug 7, 2023

The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking...

Company Medical Device

Venus Medtech Receives FDA IDE Approval for VenusP-Valve, a Milestone for Chinese Heart Valve Technology

Fineline Cube Aug 7, 2023

Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced obtaining Investigational Device Exemption (IDE) approval from...

Company Medical Device

MicroPort CardioFlow Announces Positive Results for Transcatheter Mitral Valve Replacement System

Fineline Cube Aug 7, 2023

China-based MicroPort Scientific Corp’s spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced positive...

Company Deals

Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation

Fineline Cube Aug 7, 2023

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...

Company Deals

Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China

Fineline Cube Aug 7, 2023

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...

Posts pagination

1 … 483 484 485 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.